Alvin J. Siteman Cancer Center

Washington University Medical Campus

St. Louis, MO

Sorting 18 by

Accepting patients

DISC-0974

A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Learn more
  • Monoclonal Antibody
  • Hemojuvelin (HJV)
  • Monotherapy
  • Randomization
  • Phase 1/2

Accepting patients

Atorvastatin vs. Rosuvastatin

Pilot Study of Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)
Learn more
  • Statin
  • Phase 2

Accepting patients

DEC-C Post-Transplant

A Phase I/II Trial of Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Learn more
  • Cytidine Deaminase Inhibitor
  • Phase 1/2

Accepting patients

ChromoSeq

A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
Learn more
  • Genetic Sequencing
  • Laboratory Assay
  • Observational Trial

Accepting patients

Identification of Drug Sensitization

Identification of AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
Learn more

Accepting patients

ChromoSeq

A Prospective Study of Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Learn more
  • Laboratory Assay
  • Observational Trial

Accepting patients

AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more
  • Kinase Inhibitor
  • Phase 1

Accepting patients

CC-91633 (BMS-986397)

A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Learn more
  • CELMoD
  • Phase 1

Accepting patients

Mismatched Related vs. Matched Unrelated Donor

A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Learn more
  • Allogeneic Stem Cell Transplant
  • Monoclonal Antibody
  • Phase 3

Accepting patients

Maintenance Ruxolitinib

Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Learn more
  • JAK2 Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • Maintenance
  • Phase 2